Editors' page

Abstract

In this issue of the journal we highlight important and controversial issues which affect patient management. There is currently an ongoing debate about the use of Dabigatran and the lack of need for monitoring the level of anticoagulation, which has previously been claimed to be one of the most important advantages of the drug. Furthermore, the RE-LY study has come under scrutiny, as has the drug company's disclosure of data and the FDA's handling of the issue.

All these issues have been highlighted in detail by Dr Kaba and colleagues in their News And Views article. We invite comments from the readership about the issues raised in this important article.